Monocyte chemoattractant protein-1 in patients with systemic lupus erythematosus and its correlation with disease activity
- VernacularTitle:系统性红斑狼疮患者血浆单核细胞化学吸引蛋白-1检测及其临床意义
- Author:
Fengxia WU
;
Lijun WU
;
Yufeng QING
;
Ningtao LIU
;
Chuanmei XIE
;
Minghui YANG
;
Jingguo ZHOU
;
Guohua YUAN
- Publication Type:Journal Article
- Keywords:
Lupus erythematosus,systemic;
Chemotactic factors;
Monocyte chemoattractant protein-1
- From:
Chinese Journal of Rheumatology
2008;12(10):704-706
- CountryChina
- Language:Chinese
-
Abstract:
Objective To determine the level of monocyte chemoattractant protein-1 (MCP-1) in patients with systemic lupus erythematosus (SLE) and to assess its relationship with disease activity and organ damage. Methods The plasma levels of MCP-I were measured by enzyme linked immunosorbent assay (ELISA) in 95 patients with SLE and 21 healthy controls. Disease activity in SLE patients was assessed using the SLE Disease Activity Index (SLEDAI). Results Plasma level of MCP-1 was significantly elevated in SLE patients than in healthy controls [(849±289) pg/ml vs (426±266) pg/ml, P<0.01]. Moreover, level of MCP-1 was significantly higher in SLE patients with lupus nephritis (LN) than in patients without LN (P<0.01), andin SLE patients with neuropsychiatric symptoms than in patients without neuropsychiatric involvement (P< 0.01). In addition, significant correlation between plasma MCP-I levels and the SLEDAI was observed (r= 0.3699, P<0.01), and this relationship was not influenced by the treatment with glucocorticoid and cyclophosphamide. Conclusion MCP-I may play an important role in the pathogenesis of SLE, including renal and neuropsychiatric involvement. MCP-I is also a serologic marker of disease activity in patients with SLE, and its measurement in SLE patients may be useful for the evaluation of disease activity.
